PROCEPT BioRobotics (PRCT) Projected to Release Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $92.64 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The business had revenue of $83.13 million for the quarter, compared to the consensus estimate of $80.52 million. During the same period in the prior year, the business posted ($0.45) earnings per share. PROCEPT BioRobotics’s revenue was up 20.1% compared to the same quarter last year. On average, analysts expect PROCEPT BioRobotics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock traded up $0.14 during midday trading on Tuesday, hitting $17.82. The company’s stock had a trading volume of 351,160 shares, compared to its average volume of 1,564,884. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -9.77 and a beta of 0.87. PROCEPT BioRobotics has a 1-year low of $16.67 and a 1-year high of $55.32. The company has a 50-day moving average price of $23.18 and a two-hundred day moving average price of $25.57.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Evercore began coverage on shares of PROCEPT BioRobotics in a report on Wednesday, June 24th. They set an “outperform” rating and a $30.00 target price on the stock. Leerink Partners lowered PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $31.00 to $29.00 in a research note on Thursday, June 11th. Citigroup cut PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Friday, July 17th. Finally, UBS Group downgraded shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective on the stock. in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $33.45.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: UBS downgraded PROCEPT BioRobotics from “Buy” to “Neutral” while setting a $20 price target, implying approximately 12.5% upside from the referenced share price. The downgrade suggests UBS sees limited near-term catalysts or a less favorable risk-reward profile, even though its target remains above the market price. Finviz report
• Negative Sentiment: Multiple law firms publicized a securities class-action lawsuit concerning investors who purchased PRCT shares between February 28, 2024, and February 25, 2026. The complaints reportedly focus on alleged securities-law violations and undisclosed inventory issues that were followed by an approximately 18% stock decline. The allegations have not been proven, but the litigation creates reputational, legal-cost and potential financial risks for the company. Investors have until September 22, 2026, to seek appointment as lead plaintiff. Kahn Swick & Foti lawsuit notice
• Negative Sentiment: An independent Seeking Alpha analysis highlighted that PROCEPT’s robotic systems may be filling more slowly than management’s placement targets, raising concerns about adoption, sales execution and the pace of revenue growth. This adds to investor worries following the company’s recent earnings miss on EPS, despite revenue growth. Seeking Alpha analysis

Institutional Trading of PROCEPT BioRobotics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in PROCEPT BioRobotics in the fourth quarter valued at about $469,000. T. Rowe Price Investment Management Inc. increased its stake in shares of PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock valued at $102,919,000 after buying an additional 1,218,815 shares during the period. Invesco Ltd. raised its holdings in PROCEPT BioRobotics by 19.8% in the 4th quarter. Invesco Ltd. now owns 43,570 shares of the company’s stock valued at $1,371,000 after buying an additional 7,191 shares during the last quarter. EP Wealth Advisors LLC acquired a new stake in PROCEPT BioRobotics during the 4th quarter worth approximately $300,000. Finally, Mackenzie Financial Corp grew its holdings in PROCEPT BioRobotics by 8.2% during the 4th quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock worth $49,512,000 after acquiring an additional 118,971 shares during the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.